Last reviewed · How we verify
Placebo (for Prednisone)
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Control arm in clinical trials comparing prednisone efficacy.
At a glance
| Generic name | Placebo (for Prednisone) |
|---|---|
| Also known as | Lactose filler to mimic 20 mg prednisone tablet, Prednisone placebo 1 tab once daily in arms 1 and 2 |
| Sponsor | Hospital for Special Surgery, New York |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials. Any observed clinical benefit results from expectation, conditioning, and the natural history of disease rather than direct molecular action. In this context, it serves as a comparator to prednisone's immunosuppressive and anti-inflammatory effects.
Approved indications
- Control arm in clinical trials comparing prednisone efficacy
Common side effects
Key clinical trials
- Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder (EARLY_PHASE1)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (PHASE3)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (PHASE3)
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (PHASE3)
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (PHASE3)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Prednisone) CI brief — competitive landscape report
- Placebo (for Prednisone) updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI